Limited value of cabergoline in Cushing's disease: a prospective study of a 6-week treatment in 20 patients.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  European Journal of Endocrinology

• Publication date

  2015-11-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1530/EJE-15-0807PMID 26582653
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study

  2014influential reference
• Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.

  2013cited by this paper
• Cushing's syndrome: a structured short- and long-term management plan for patients in remission.

  2013cited by this paper
• High variability in baseline urinary free cortisol values in patients with Cushing’s disease

  2013cited by this paper
• Measurement of salivary cortisol in 2012 – laboratory techniques and clinical indications

  2012cited by this paper
• Macrocorticotropinoma shrinkage and control of hypercortisolism under long-term cabergoline therapy: case report

  2012cited by this paper
• Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease

  2010cited by this paper
• Cabergoline monotherapy in the long-term treatment of Cushing's disease.

  2010cited by this paper
• High Prevalence of Normal Tests Assessing Hypercortisolism in Subjects with Mild and Episodic Cushing's Syndrome Suggests that the Paradigm for Diagnosis and Exclusion of Cushing's Syndrome Requires Multiple Testing

  2010cited by this paper
• Differential expression of somatostatin and dopamine receptor subtype genes in adrenocorticotropin (ACTH)-secreting pituitary tumors and silent corticotroph adenomas.

  2009cited by this paper
• Effect of injectable bromocriptine in patients with Cushing's disease.

  2009cited by this paper
• Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

  2009cited by this paper
• The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.

  2009cited by this paper
• Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement.

  2008cited by this paper
• The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

  2008cited by this paper
• Cyclic Cushing's syndrome: a clinical challenge.

  2007cited by this paper
• Limitations of nocturnal salivary cortisol and urine free cortisol in the diagnosis of mild Cushing's syndrome.

  2007cited by this paper
• Effect of cabergoline treatment on Cushing’s disease caused by aberrant adrenocorticotropin-secreting macroadenoma

  2004cited by this paper
• Nelson’s Syndrome: Complete Remission with Cabergoline but Not with Bromocriptine or Cyproheptadine Treatment

  2004cited by this paper
• Dopamine receptor expression and function in corticotroph pituitary tumors.

  2004cited by this paper
• Macroprolactinoma associated with Cushing’s disease, successfully treated with cabergoline

  2002cited by this paper
• ACTH silent adenoma shrinking under cabergoline.

  2001cited by this paper
• Dopamine D2 receptor gene expression in human adenohypophysial adenomas

  2001cited by this paper
• Dopamine as a prolactin (PRL) inhibitor.

  2001cited by this paper
• The diagnosis of Cushing's syndrome: atypical presentations and laboratory shortcomings.

  2000cited by this paper
• Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline

  1999cited by this paper
• Beneficial effects of high daily dose bromocriptine treatment in Cushing's disease.

  1992cited by this paper
• Dopamine agonists and pituitary tumor shrinkage.

  1992cited by this paper
• Variable hormonogenesis in Cushing's syndrome.

  1991cited by this paper
• THE EFFECT OF CYPROHEPTADINE AND/OR BROMOCRIPTINE ON PLASMA ACTH LEVELS IN PATIENTS CURED OF CUSHING'S DISEASE BY BILATERAL ADRENALECTOMY

  1990cited by this paper
• A BROMOCRIPTINE‐RESPONSIVE CORTICOTROPH ADENOMA SECRETING α‐MSH IN A PATIENT WITH CUSHING'S DISEASE

  1988cited by this paper
• LONG‐LASTING LOWERING OF SERUM GROWTH HORMONE AND PROLACTIN LEVELS BY SINGLE AND REPETITIVE CABERGOLINE ADMINISTRATION IN DOPAMINE‐RESPONSIVE ACROMEGALIC PATIENTS

  1988cited by this paper
• RESPONSE TO NEUROTRANSMITTER MODULATING DRUGS IN PATIENTS WITH CUSHING'S DISEASE

  1986cited by this paper
• EFFECT OF BROMOCRIPTINE IN PITUITARY‐DEPENDENT CUSHING'S SYNDROME

  1983cited by this paper
• The mechanism of the suppressive action of bromocriptine on adrenocorticotropin secretion in patients with Cushing's disease and Nelson's syndrome.

  1980cited by this paper
• Lack of effect of bromocriptine on ACTH levels in patients with bilateral adrenalectomy for pituitary-dependent Cushing’s syndrome

  1978cited by this paper
• ACTH and cortisol response to bromocriptine, and results of long-term therapy, in Cushing's disease.

  1978cited by this paper
• Effect of bromocriptine in pituitary-dependent Cushing's syndrome.

  1976cited by this paper
• Relationship of bioassayable and immunoassayable plasma ACTH and cortisol concentrations in normal subjects and in patients with Cushing's disease.

  1975cited by this paper

• Medical Therapies of Cushing's Disease-Part 1.

  2025cites this paper
• Medical Treatment of Cushing’s Syndrome

  2025influential citation
• Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas.

  2025cites this paper
• A Case of Spontaneously Resolving Cushing Disease

  2025cites this paper
• Update on Medical Treatment of Cushing’s Syndrome

  2025cites this paper
• How to manage Cushing's disease after failed primary pituitary surgery.

  2024cites this paper
• From Nelson’s Syndrome to Corticotroph Tumor Progression Speed: An Update

  2024cites this paper
• 库欣病的内科药物治疗新进展（英文）

  2024influential citation
• Drug induced hypoprolactinemia

  2024cites this paper
• Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease

  2023cites this paper
• Medical treatment of Cushing’s disease with concurrent diabetes mellitus

  2023cites this paper
• An evaluation of pharmacological options for Cushing’s disease: what are the state-of-the-art options?

  2023cites this paper
• The dopaminergic control of Cushing’s syndrome

  2022cites this paper
• Current and Emerging Medical Therapies in Pituitary Tumors

  2022cites this paper
• Innovative tumour targeting therapeutics in Cushing's disease.

  2022cites this paper
• Medical management of Cushing's disease

  2021cites this paper
• Targeting Aggressive Pituitary Adenomas at the Molecular Level—A Review

  2021cites this paper
• The effects of cabergoline in the presurgical and recurrence periods of Cushing's disease patients.

  2021cites this paper
• Consensus on diagnosis and management of Cushing's disease: a guideline update.

  2021cites this paper
• Effectiveness of Medical Treatment of Cushing’s Disease: A Systematic Review and Meta-Analysis

  2021cites this paper
• Advances in the Medical Treatment of Cushing Disease.

  2020cites this paper
• The Role of Dopamine Agonists in Pituitary Adenomas.

  2020cites this paper
• Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery

  2020cites this paper
• Cushing's syndrome: Treatment and new therapeutic approaches.

  2020cites this paper
• Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.

  2020cites this paper
• Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials

  2020cites this paper
• Updates in the Medical Treatment of Pituitary Adenomas

  2019cites this paper
• Advances in the medical treatment of Cushing's syndrome.

  2019cites this paper
• Pituitary Disease in Pregnancy: Special Aspects of Diagnosis and Treatment?

  2019cites this paper
• Therapeutic options after surgical failure in Cushing's disease: A critical review.

  2019cites this paper
• Medical Management of Cushing’s Syndrome: Current and Emerging Treatments

  2019cites this paper
• Medical Management of Cushing Disease.

  2019cites this paper
• THE MULTIFARIOUS CUSHING'S - LESSONS FROM A CASE SERIES.

  2019cites this paper
• Current management of Cushing's disease

  2019cites this paper
• Treatment of Pituitary and Other Tumours with Cabergoline: New Mechanisms and Potential Broader Applications

  2019cites this paper
• Pituitary-Directed Therapies for Cushing’s Disease

  2018influential citation
• Tratamento medicamentoso da Doença de Cushing: revisão sistemática da literatura e metanálise

  2018cites this paper
• Marked Response of a Hypermutated ACTH-Secreting Pituitary Carcinoma to Ipilimumab and Nivolumab

  2018cites this paper
• New and emerging drug therapies for Cushing’s disease

  2018cites this paper
• Effectiveness of medical treatment for Cushing’s syndrome: a systematic review and meta-analysis

  2018cites this paper
• New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A

  2018cites this paper
• A review of Cushing's disease treatment by the Department of Neuroendocrinology of the Brazilian Society of Endocrinology and Metabolism

  2018cites this paper
• European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas.

  2018cites this paper
• Medical Therapy for Cushing's Syndrome in the Twenty-first Century.

  2018cites this paper
• Tumor-Directed Therapeutic Targets in Cushing Disease.

  2018cites this paper
• Dopamine Agonists for Pituitary Adenomas

  2018cites this paper
• Effect of cabergoline monotherapy in Cushing’s disease: an individual participant data meta-analysis

  2018cites this paper
• An unusual case of Cushing's syndrome due to bihormonal ACTH–prolactin secreting pituitary macroadenoma with rapid response to cabergoline

  2017cites this paper
• Recent Progress in the Medical Therapy of Pituitary Tumors

  2017cites this paper
• Pharmacological Management of Cushing ’ s Disease

  2017cites this paper
• Cabergoline for Cushing's disease: a large retrospective multicenter study.

  2017cites this paper
• Chapter 17 – Cushing Disease

  2017cites this paper
• Update on medical treatment for Cushing’s disease

  2016cites this paper
• Medical treatment of Cushing's Disease.

  2016cites this paper